Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1977 1
1978 1
1980 1
1982 3
1983 1
1984 4
1985 5
1986 6
1987 8
1988 16
1989 4
1990 3
1991 1
1992 5
1993 5
1994 6
1995 5
1996 1
1997 1
1998 1
1999 8
2000 9
2001 10
2002 11
2003 17
2004 11
2005 16
2006 11
2007 23
2008 17
2009 16
2010 24
2011 13
2012 12
2013 27
2014 42
2015 49
2016 49
2017 66
2018 84
2019 89
2020 115
2021 123
2022 118
2023 116
2024 139
2025 133
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,255 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: mohammadrahimpanah
Page 1
Behcet's disease.
Davatchi F. Davatchi F. Int J Rheum Dis. 2014 May;17(4):355-7. doi: 10.1111/1756-185X.12378. Epub 2014 Apr 25. Int J Rheum Dis. 2014. PMID: 24762121 No abstract available.
A brief history of NEDA.
Giovannoni G, Bermel R, Phillips T, Rudick R. Giovannoni G, et al. Mult Scler Relat Disord. 2018 Feb;20:228-230. doi: 10.1016/j.msard.2017.07.011. Epub 2017 Jul 13. Mult Scler Relat Disord. 2018. PMID: 29579628 No abstract available.
Are we in need of NEDA?
Freedman MS. Freedman MS. Mult Scler. 2016 Jan;22(1):5-6. doi: 10.1177/1352458515617249. Epub 2015 Nov 9. Mult Scler. 2016. PMID: 26552731 No abstract available.
The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI.
Di Sabatino E, Gaetani L, Sperandei S, Fiacca A, Guercini G, Parnetti L, Di Filippo M. Di Sabatino E, et al. J Neurol. 2022 Jun;269(6):3129-3135. doi: 10.1007/s00415-021-10901-2. Epub 2021 Nov 24. J Neurol. 2022. PMID: 34820734
METHODS: We included 115 pwMS undergoing treatment with first-line disease-modifying therapies (DMTs) and retrospectively analyzed the presence of NEDA in the whole cohort, either considering or not spinal cord imaging. RESULTS: When considering only clinical and brain MRI …
METHODS: We included 115 pwMS undergoing treatment with first-line disease-modifying therapies (DMTs) and retrospectively analyzed the prese …
Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population.
Simonsen CS, Flemmen HØ, Broch L, Brekke K, Brunborg C, Berg-Hansen P, Celius EG. Simonsen CS, et al. Front Neurol. 2022 Nov 14;13:1034056. doi: 10.3389/fneur.2022.1034056. eCollection 2022. Front Neurol. 2022. PMID: 36452173 Free PMC article.

PwMS who achieved NEDA at year one had a mean time to EDSS 6 of 33.8 (95% CI 30.9-36.8) years vs. 30.8 (95% CI 25.0-36.6) years in pwMS who did not achieve NEDA, p < 0.001. When rebaselining NEDA 1 year after diagnosis, 52.2% achieved NEDA in the 1s

…
PwMS who achieved NEDA at year one had a mean time to EDSS 6 of 33.8 (95% CI 30.9-36.8) years vs. 30.8 (95% CI 25.0-36.6) years in pw …
Beyond Efficacy: Persistence, NEDA, and Therapeutic Decision-Making in First-Line Multiple Sclerosis Treatment.
López-Caneda CH, Antón-Fuente S, Pérez-Haro MJ, Sánchez-Franco CM, Alvarez-Rodríguez E, Aguado-Valcarcel M, Marcos-Bobillo M, Torrente-Carballido M, González-Suárez I. López-Caneda CH, et al. Neurol Ther. 2025 Oct;14(5):2095-2106. doi: 10.1007/s40120-025-00811-0. Epub 2025 Aug 12. Neurol Ther. 2025. PMID: 40794358 Free PMC article.
Effectiveness was evaluated using cumulative no evidence of disease activity (NEDA)-2 and NEDA-3 status. NEDA-2 included the absence of clinical relapses and confirmed disability progression; NEDA-3 additionally required the lack of MRI activity. ...No …
Effectiveness was evaluated using cumulative no evidence of disease activity (NEDA)-2 and NEDA-3 status. NEDA-2 include …
Neda Leonard: Filling a Void.
[No authors listed] [No authors listed] Consult Pharm. 2017 May 1;32(5):256-257. doi: 10.4140/TCP.n.2017.256. Consult Pharm. 2017. PMID: 28483005 No abstract available.
Self-injectable DMTs in relapsing MS: NEDA assessment at 10 years in a real-world cohort.
Ozakbas S, Piri Cinar B, Baba C, Kosehasanogullari G, Sclerosis Research Group M. Ozakbas S, et al. Acta Neurol Scand. 2022 May;145(5):557-564. doi: 10.1111/ane.13582. Epub 2022 Jan 19. Acta Neurol Scand. 2022. PMID: 35043388
Monitoring the efficacy of DMTs with no evidence disease activity (NEDA) provides an objective perspective for evaluating treatment success. OBJECTIVE: Our goal is to detect the prevalence of NEDA-3 in people with MS treated with self-injectable DMTs at two years an …
Monitoring the efficacy of DMTs with no evidence disease activity (NEDA) provides an objective perspective for evaluating treatment s …
Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.
Rodríguez-Jorge F, Fernández-Velasco JI, Villarrubia N, Gracia-Gil J, Fernández E, Meca-Lallana V, Díaz-Pérez C, Sainz de la Maza S, Pacheco EM, Quiroga A, Ramió-Torrentà L, Martínez-Yélamos S, Bau L, Monreal E, López-Real A, Rodero-Romero A, Borrega L, Díaz S, Eguía P, Espiño M, Chico-García JL, Barrero FJ, Martínez-Ginés ML, García-Domínguez JM, De la Fuente S, Moreno I, Sainz-Amo R, Mañé-Martínez MA, Caminero A, Castellanos F, Gómez López A, Labiano-Fontcuberta A, Ayuso L, Abreu R, Hernández MÁ, Meca-Lallana J, Martín-Aguilar L, Muriel García A, Masjuan J, Costa-Frossard L, Villar LM. Rodríguez-Jorge F, et al. Front Immunol. 2024 Nov 12;15:1480676. doi: 10.3389/fimmu.2024.1480676. eCollection 2024. Front Immunol. 2024. PMID: 39606235 Free PMC article.

RESULTS: After a year on ocrelizumab, 85 patients (73.9%) achieved NEDA-3. Thirty patients did not achieve NEDA: 20 (17.4%) because of INFL and 10 (8.7%) because of PIRA. ...After a year, NEDA-3 and INFL patients showed similar decreases in sNfL (p < 0.000

…
RESULTS: After a year on ocrelizumab, 85 patients (73.9%) achieved NEDA-3. Thirty patients did not achieve NEDA: 20 (17.4%) be …
1,255 results